Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Infectious Diseases and Therapy
|
February 16, 2026
A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19
Ilker Yalcin, Leijun Hu, Brandyn West, et al.
The Journal of Infectious Diseases
|
May 21, 2026
Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19
Kristin Narayan, Kazima Tosh, Anna Holmes, et al.
Infectious Diseases and Therapy
|
May 15, 2023
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
Pete Schmidt, Jean Gong, Kristin Narayan, et al.
Mabs
|
June 28, 2018
Extending human IgG half-life using structure-guided design
Brian J Booth, Boopathy Ramakrishnan, Kristin Narayan, et al.
Ebiomedicine
|
January 15, 2019
Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study
Ellie Hershberger, Susan Sloan, Kristin Narayan, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 27, 2022
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
Pete Schmidt, Kristin Narayan, Yong Li, et al.
Open Forum Infectious Diseases
|
July 27, 2023
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
Michael G Ison, Debra F Weinstein, Marta Dobryanska, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 23, 2025
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)
Cameron R Wolfe, Jonathan Cohen, Kathryn Mahoney, et al.
Science Translational Medicine
|
March 22, 2023
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
Pete Schmidt, Kristin Narayan, Yong Li, et al.
Open Forum Infectious Diseases
|
June 23, 2023
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
Michael G Ison, Myra Popejoy, Nikolay Evgeniev, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Infectious Diseases and Therapy
|
February 16, 2026
A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19
Ilker Yalcin, Leijun Hu, Brandyn West, et al.
The Journal of Infectious Diseases
|
May 21, 2026
Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19
Kristin Narayan, Kazima Tosh, Anna Holmes, et al.
Infectious Diseases and Therapy
|
May 15, 2023
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
Pete Schmidt, Jean Gong, Kristin Narayan, et al.
Mabs
|
June 28, 2018
Extending human IgG half-life using structure-guided design
Brian J Booth, Boopathy Ramakrishnan, Kristin Narayan, et al.
Ebiomedicine
|
January 15, 2019
Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study
Ellie Hershberger, Susan Sloan, Kristin Narayan, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 27, 2022
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
Pete Schmidt, Kristin Narayan, Yong Li, et al.
Open Forum Infectious Diseases
|
July 27, 2023
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
Michael G Ison, Debra F Weinstein, Marta Dobryanska, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 23, 2025
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)
Cameron R Wolfe, Jonathan Cohen, Kathryn Mahoney, et al.
Science Translational Medicine
|
March 22, 2023
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
Pete Schmidt, Kristin Narayan, Yong Li, et al.
Open Forum Infectious Diseases
|
June 23, 2023
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
Michael G Ison, Myra Popejoy, Nikolay Evgeniev, et al.
Page
of 2